Been scrolling through some interesting plays in the penny stock space lately, and wanted to share a few that caught my attention back in 2023. These companies had some solid catalysts brewing, so worth looking back at what was happening with them.

First up is Savara. They're a biotech outfit working on rare respiratory diseases, which honestly is a pretty specific niche. What made them stand out was their Phase 3 trial for this lung disease treatment called molgramostim. They actually exceeded their enrollment target with 164 patients, which is pretty solid for a clinical-stage company dealing with rare diseases. They had decent cash on hand too around $105 million, plus they raised another $80 million from a stock offering. The real milestone was completing that IMPALA-2 trial enrollment.

Then there's Canaan, which is basically the hardware supplier for Bitcoin mining operations. Their numbers in mid-2023 were pretty impressive - they hit $73.9 million in revenue that quarter, up from $55.2 million the previous one. Their computing power was climbing too. But they ran into some regulatory headwinds in Kazakhstan where mining got stricter. Still, they managed to lock down a partnership with Cipher Mining to keep expanding.

Ardelyx is the third one I was watching. They're a pharma company with a commercial product already generating real revenue. Their IBSRELA was pulling in around $18.3 million per quarter, and they were expecting $72-77 million in annual revenue for 2023. They had solid cash reserves and were pushing their tenapanor application through in China with FDA review happening in the US too. Expected US launch was supposed to happen by Q4 2023.

Looking back at penny stocks to buy from that era, these three had different angles but all had actual value catalysts - not just hype. Biotech with trial data, hardware supplier with partnership deals, pharma with revenue already flowing. That's the kind of differentiation worth paying attention to when you're looking at smaller cap opportunities.